- Home
- ATAI vs HURA Comparison
ATAI vs HURA Comparison
Compare ATAI & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- HURA
- Stock Information
- Founded
- ATAI 2018
- HURA 2009
- Country
- ATAI Netherlands
- HURA United States
- Employees
- ATAI N/A
- HURA N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- HURA
- Sector
- ATAI Health Care
- HURA
- Exchange
- ATAI Nasdaq
- HURA Nasdaq
- Market Cap
- ATAI 1.1B
- HURA 131.8M
- IPO Year
- ATAI 2021
- HURA N/A
- Fundamental
- Price
- ATAI $5.85
- HURA $2.29
- Analyst Decision
- ATAI Strong Buy
- HURA Strong Buy
- Analyst Count
- ATAI 5
- HURA 2
- Target Price
- ATAI $14.00
- HURA $11.50
- AVG Volume (30 Days)
- ATAI 7.0M
- HURA 181.8K
- Earning Date
- ATAI 11-12-2025
- HURA 11-13-2025
- Dividend Yield
- ATAI N/A
- HURA N/A
- EPS Growth
- ATAI N/A
- HURA N/A
- EPS
- ATAI N/A
- HURA N/A
- Revenue
- ATAI $2,309,000.00
- HURA N/A
- Revenue This Year
- ATAI $736.04
- HURA N/A
- Revenue Next Year
- ATAI N/A
- HURA N/A
- P/E Ratio
- ATAI N/A
- HURA N/A
- Revenue Growth
- ATAI 510.85
- HURA N/A
- 52 Week Low
- ATAI $1.04
- HURA $1.80
- 52 Week High
- ATAI $6.75
- HURA $7.20
- Technical
- Relative Strength Index (RSI)
- ATAI 55.30
- HURA 39.99
- Support Level
- ATAI $5.50
- HURA $2.16
- Resistance Level
- ATAI $6.73
- HURA $2.61
- Average True Range (ATR)
- ATAI 0.50
- HURA 0.13
- MACD
- ATAI -0.04
- HURA -0.02
- Stochastic Oscillator
- ATAI 44.14
- HURA 25.51
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.